Drug Delivery Business

Lilly pays $50 million upfront to use Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology

By

Entos/LillyEli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology.

Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products intended for the nervous system.

Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities.

Get the full story from our sister site, Drug Discovery & Development.

IN CASE YOU MISSED IT

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].